Orexo AB (publ) (STO:ORX)
Sweden · Delayed Price · Currency is SEK 29.80
-0.25 (-0.84%)
Feb 10, 2026, 5:29 PM CET
Orexo AB Revenue
In the year 2025, Orexo AB had annual revenue of 26.00M SEK, down -95.59%. Orexo AB had revenue of 3.30M in the quarter ending December 31, 2025, a decrease of -97.94%.
Revenue
26.00M
Revenue Growth
-95.59%
P/S Ratio
39.55
Revenue / Employee
361.11K
Employees
72
Market Cap
1.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.00M | -564.00M | -95.59% |
| Dec 31, 2024 | 590.00M | -48.80M | -7.64% |
| Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
| Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
| Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.46B |
| EQL Pharma AB | 425.75M |
| Enzymatica AB | 52.73M |
| Cinclus Pharma Holding AB | 48.42M |
| Cereno Scientific AB | 46.66M |
| Nanexa AB | 31.92M |
| Moberg Pharma AB | 12.50M |
| Klaria Pharma Holding AB (publ.) | 10.05M |
Orexo AB News
- 17 hours ago - Orexo AB (ORXOF) Q4 2025 Earnings Call Highlights: Strategic Divestment and Financial Resilience - GuruFocus
- 18 hours ago - Q4 2025 Orexo AB Earnings Call Transcript - GuruFocus
- 4 days ago - Orexo AB (publ) 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 4 days ago - Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript - Seeking Alpha
- 3 months ago - Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Orexo AB (ORXOF) Q3 2025 Earnings Call Highlights: Promising R&D Progress Amidst Market ... - GuruFocus
- 3 months ago - Orexo AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha